title: Accelerated plasminogen activator inhibitor may prevent late restenosis after coronary stenting in acute myocardial infarction.
abstract: BACKGROUND
  Although acceleration of plasma plasminogen activator inhibitor-1 (PA-1) level after emergent coronary angioplasty in acute myocardial infarction (AMI) has been documented, its pathophysiologic role is still unknown.
  
  
  OBJECTIVE
  This study was designed to elucidate the role of PAI-1 in the development of restenosis after primary coronary stenting in AMI.
  
  
  METHODS
  We selected for this study 66 patients with AMI, who underwent primary coronary stenting for infarct-related coronary artery lesions in an emergent situation. In all patients, plasma PAI-1 level was measured at admission, and at 3 h, 24 h, 48 h, and 1 month after coronary stenting.
  
  
  RESULTS
  At admission, the PAI-1 level was equivalent in 24 patients who experienced restenosis and in 42 patients without restenosis (28 +/- 4 vs. 29 +/- 4 ng/ml). In patients with restenosis, the levels did not change during the course after coronary stenting. In patients without restenosis, however, the level significantly increased at 3 h (48 +/- 9 ng/ml, p < 0.001), 24 h (42 +/- 9, p < 0.01), and 48 h (38 +/- 7, p < 0.05) after coronary stenting, and was restored to the level equivalent to that at admission (27 +/- 2 ng/ml) I month aftercoronary stenting. The PA-1 level at 3 h after coronary stenting in patients without restenosis was significantly higher (p < 0.05) than the level (33 +/- 6 ng/ml) in patients with restenosis. Multiple logistic regression analysis indicated that the PAI-1 level 3 h after coronary stenting was an independent predictor of restenosis (Wald chi2 = 3.826, p = 0.019, odds ratio 0.921, 95% confidence interval 0.866-0.961).
  
  
  CONCLUSIONS
  Accelerated PAI-1 after coronary stenting in patients with AMI may protect against the development of late restenosis.
authors.affiliation: Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya-City, Saitama, Japan. inouet@dokkyomed.ac.jp
authors.forename: Teruo
authors.initials: T
authors.lastname: Inoue
authors.forename: Isao
authors.initials: I
authors.lastname: Yaguchi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Mizoguchi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Uchida
authors.forename: Kan
authors.initials: K
authors.lastname: Takayanagi
authors.forename: Terumi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Shigenori
authors.initials: S
authors.lastname: Morooka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Eguchi
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D006328:Cardiac Catheterization; D016022:Case-Control Studies; D016001:Confidence Intervals; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000517:prevention & control*; D003422:Critical Care; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D016017:Odds Ratio; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000378:metabolism*; D011446:Prospective Studies; D012016:Reference Values; D012494:Sampling Studies; D012720:Severity of Illness Index; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D017395:Plasminogen Activator Inhibitor 1